SELLAS Life Sciences Group, Inc.: directors' dealings · United States · SEC (Form 4)

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a U.S.-listed clinical-stage biopharmaceutical company headquartered in New York, United States. Founded in 2012, SELLAS is built around an oncology-focused R&D model rather than a commercial pharmaceutical platform, which means its valuation is primarily driven by clinical milestones, regulatory feedback, and financing events. For investors, this places the company in the high-risk/high-reward segment of small-cap biotechnology, where share price performance can react sharply to trial data and capital raises. ([ir.sellaslifesciences.com](https://ir.sellaslifesciences.com/company/default.aspx?utm_source=openai)) The company’s strategy is centered on two main assets: galinpepimut-S (GPS) and SLS009. GPS is a cancer immunotherapeutic licensed from Memorial Sloan Kettering Cancer Center and is being developed most notably in acute myeloid leukemia (AML) through the pivotal Phase 3 REGAL trial. SLS009 is a targeted oncology candidate also being advanced in AML, with SELLAS reporting positive Phase 2 data in relapsed/refractory AML in 2025 and moving the program toward a first-line study. Together, these programs give SELLAS exposure to hematologic oncology, an area with persistent unmet medical need and a strong appetite for differentiated mechanisms. ([ir.sellaslifesciences.com](https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Provides-Update-on-Pivotal-Phase-3-REGAL-Trial-of-Galinpepimut-S-GPS-in-Acute-Myeloid-Leukemia-AML/?utm_source=openai)) In competitive terms, SELLAS remains a development-stage biotech with limited diversification. Its upside depends on whether its lead programs can deliver clinically meaningful efficacy and eventually support regulatory approval and, if successful, commercialization or partnering. The company’s competitive positioning comes from the novelty of its approaches and the fact that both core assets are already in relatively advanced stages, which can create near-term catalysts. At the same time, the stock retains the classic biotech risks: binary trial outcomes, dilution risk, and the possibility that clinical timelines slip. Recent filings and corporate updates also show ongoing attention to balance-sheet management, including warrant exercises that improved cash resources in 2025 and 2026. ([ir.sellaslifesciences.com](https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Reports-First-Quarter-2025-Financial-Results-and-Provides-Corporate-Update/default.aspx?utm_source=openai)) Geographically, SELLAS operates from New York, United States, and relies on a network of research and clinical partners to run its development programs. Major recent news has focused on the progression of the REGAL Phase 3 trial for GPS, the count of events required for final analysis, the expansion of SLS009 into newly diagnosed AML, and the company’s latest quarterly and full-year updates. For French-speaking investors in France, Belgium, and Switzerland, SELLAS is best viewed as a U.S. NASDAQ-listed oncology biotech with a concentrated pipeline, meaningful clinical catalysts, and a valuation profile that will likely remain highly sensitive to data releases and financing conditions. ([ir.sellaslifesciences.com](https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update/default.aspx?utm_source=openai))